HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Asenapine modulates mood-related behaviors and 5-HT1A/7 receptors-mediated neurotransmission.

AbstractAIM:
Asenapine is a new atypical antipsychotic prescribed for the treatment of psychosis/bipolar disorders that presents higher affinity for serotonergic than dopaminergic receptors. The objective of this study was to investigate its antidepressant-like and antimanic-like properties on relevant animal models of depression and mania and to assess the acute and chronic effect of Asenapine on dorsal raphe nucleus (DRN) 5-HT cell firing activity.
METHODS:
We assessed the effects of Asenapine using in vivo electrophysiological and behavioral assays in rats.
RESULTS:
Behavioral experiments showed that Asenapine had no significant effect on immobility time in the forced swim test (FST) in control rats. In the ACTH-treated rats, a model of antidepressant-resistance, Asenapine failed to alter immobility time in the FST. In contrast in the sleep deprivation (SD) model of mania, acute administration of Asenapine significantly decreased the hyperlocomotion of SD rats. In the DRN, acute administration of Asenapine reduced the suppressant effect of the selective 5-HT7 receptor agonist LP-44 and of the prototypical 5-HT1A receptor agonist 8-OH-DPAT on 5-HT neuronal firing activity. In addition, chronic treatment with Asenapine enhanced DRN 5-HT neuronal firing and this effect was associated with an alteration of the 5-HT7 receptor responsiveness.
CONCLUSION:
These results confirm that Asenapine displays robust antimanic property and effective in vivo antagonistic activity at 5-HT1A/7 receptors.
AuthorsSarah Delcourte, Erika Abrial, Adeline Etiévant, Renaud Rovera, Jørn Arnt, Michael Didriksen, Nasser Haddjeri
JournalCNS neuroscience & therapeutics (CNS Neurosci Ther) Vol. 23 Issue 6 Pg. 518-525 (Jun 2017) ISSN: 1755-5949 [Electronic] England
PMID28417559 (Publication Type: Journal Article)
Copyright© 2017 John Wiley & Sons Ltd.
Chemical References
  • Adrenergic alpha-2 Receptor Agonists
  • Antipsychotic Agents
  • Dibenzocycloheptenes
  • Heterocyclic Compounds, 4 or More Rings
  • Receptors, Serotonin
  • Serotonin Agents
  • serotonin 7 receptor
  • Receptor, Serotonin, 5-HT1A
  • Dexmedetomidine
  • Adrenocorticotropic Hormone
  • asenapine
Topics
  • Adrenergic alpha-2 Receptor Agonists (pharmacology)
  • Adrenocorticotropic Hormone (pharmacology)
  • Affect (drug effects, physiology)
  • Animals
  • Antipsychotic Agents (pharmacology)
  • Dexmedetomidine (pharmacology)
  • Dibenzocycloheptenes
  • Disease Models, Animal
  • Drug Delivery Systems
  • Heterocyclic Compounds, 4 or More Rings (pharmacology)
  • Male
  • Neurons (drug effects)
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Serotonin, 5-HT1A (metabolism)
  • Receptors, Serotonin (metabolism)
  • Septal Nuclei (cytology)
  • Serotonin Agents (pharmacology)
  • Sleep Deprivation (drug therapy, metabolism)
  • Swimming (psychology)
  • Synaptic Transmission (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: